TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05681507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block
Description: Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative analgesia
Description: Standard of postoperative ICU analgesic care, per institutional protocol
Study: NCT04909073

Intervention type: DRUG
Intervention: Afatinib
Description: Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
Study: NCT04753073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive physical plasma
Description: Treatment with non invasive physical low-temperature plasma
Study: NCT04765800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy
Description: according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy
Description: according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)
Study: NCT05940792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonelastic taping
Description: Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physiotherapy
Description: The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
Study: NCT04599634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
Study: NCT06323109

Intervention type: DEVICE
Intervention: MRI-UDS; US-UDS; MCUD
Description: Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.

Intervention type: DEVICE
Intervention: MRI-UDS; US-UDS; MCUD
Description: Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.
Study: NCT04599634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
Study: NCT05470127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy needle
Description: Prostate tissue biopsy with a biopsy needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy needle
Description: Prostate tissue biopsy with a biopsy needle
Study: NCT04599634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
Study: NCT05430035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
Study: NCT04599634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
Study: NCT05491668

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-hyperemic pressure ratio assessment pre and post PCI
Description: Pre and post PCI invasive physiologic assessment
Study: NCT06136585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg/kg sugammadex
Description: All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.07 mg/kg neostigmine
Description: All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
Study: NCT05113069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1912
Description: SHR-A1912, dose escalation and expansion.
Study: NCT04981535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head box during upper gastrointestinal endoscopy
Description: ็Head box is an acrylic box over a patient's head who undergoing upper gastrointestinal endoscopy.
Study: NCT04852107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation
Description: Lead Implantation which will be conducted in 2 steps:~1. Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~2. Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation
Description: Lead Implantation which will be conducted in 2 steps:~1. Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~2. Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm.
Study: NCT06320652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation (video consultation and home monitoring)
Description: Patients with cardiac disease and earlier experiences with cardiac rehabilitation, family members, and nurses in the Departments of Cardiology at Amager and Hvidovre Hospital will be invited to work in a partnership and through a course of innovative co-creative workshops. It is recommended that usability studies have 5-15 participants, which is why we plan to enroll 3 cardiac patients, 3 relatives and 3 nurses from the outpatient clinic. Through the workshops, a rehabilitation program offering cardiac telerehabilitation will be co-created to comply with the preferences and perspectives of patients and family members and nurses from the outpatient clinic. Through these workshops we will learn which important components and elements should be prioritized when offering cardiac telerehabilitation (how, when, and why?).
Study: NCT05241613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC176
Description: AC176 will be given orally (PO) on a 28-day cycle.
Study: NCT04908618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: digital impression for normal abutment
Description: Accuracy of scan body impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital impression for normal abutment
Description: Accuracy of scan body impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital impression for normal abutment
Description: Accuracy of scan body impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: open tray impression
Description: Accuracy of open tray impression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open tray impression
Description: Accuracy of open tray impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: open tray impression
Description: Accuracy of open tray impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: open tray impression
Description: Accuracy of open tray impression
Study: NCT04908618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: closed tray impression
Description: Accuracy of closed tray impression
Study: NCT06251882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection
Description: 10ml D5W injection for MP patients
Study: NCT05666427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training combined with stabilization exercises
Description: While people are doing stabilization exercises, they will also work the pelvic floor muscles. Practices will be combined with breathing.
Study: NCT04908618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed tray impression
Description: Accuracy of closed tray impression
Study: NCT05666427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Exercises that activate the pelvic floor muscles to strengthen and increase endurance.
Study: NCT05389163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Giomer based injectable resin composite
Description: Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
Study: NCT05291494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: follow the WeChat public platform to watch the education videos
Description: In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: regular preoperative visits and education by ward nurses.
Description: received oral instruction from the ward nurse covering the same contents as above instead of the education video.
Study: NCT06077266

Intervention type: OTHER
Intervention: Change of weight class to normal weight
Description: The exposure is the change of weight class from obesity to normal weight during a follow-up period without known intervention.
Study: NCT05649501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation techniques.
Description: Proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional treatment for 40 minutes.
Study: NCT05540587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~* CrCl 15-50mL/min~* Body weight ≤ 60kg~* Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
Study: NCT06067737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
Study: NCT05490550

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COAST-enhanced CBTI
Description: Participants will receive CBTI delivered through the COAST platform by one of NOCTEM's certified and licensed COAST clinician. Communication between the participant and licensed clinician will occur primarily through COAST's HIPAA-compliant text messaging, but clinicians and patients may elect to connect via telephone calls or HIPAA-compliant secure videoconference if needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Military Treatment Facility Insomnia Care As Usual
Description: Participants will receive the insomnia care offered at their site following current delivery practices (i.e., face-to-face or virtual; individual or group format). During the treatment phase, participants randomized to ICAU will be instructed to communicate with their clinicians as needed, according to standard procedures in place.
Study: NCT05562375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GOCCLES
Description: Inspection using GOCCLES®. An UV light source will be administered, with polymerization lamp sdi radii xpert, with a potency of 1500 mW/cm2 and a wavelength of 440-480nm, applied at 20cm of the injury.~Notes will be taken on the location and size of the injury observed with the device.~Image register using the GOCCLES® photographic filter for mobile devices. The same light source will be used.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Toluidine blue stain
Description: To value the toluidine blue diagnosis capacity, the sequence described by Mashberg will be followed: The patient will realize a mouthwash with acetic acid at 1% for 20 seconds. Two using water for 20 seconds. Toluidine blue at 1% will be applied for 20 seconds. New mouthwash with acetic acid for 60 seconds and a final mouthwash with water.~Notes on the and pictures will be taken on the location and size of the injury.
Study: NCT05649501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation techniques.
Description: Proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional treatment for 40 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Conventional therapy (ROMs, stretching, strengthening) of lower limbs for 40 minutes.
Study: NCT04595890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC)
Description: Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).
Study: NCT05002751

Intervention type: OTHER
Intervention: UCSD Vaginal Dilator Questionnaire
Description: 14 question survey

Intervention type: OTHER
Intervention: EORTC Sexual Health Questionnaire
Description: 22 question survey
Study: NCT05562375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: The area to biopsy will be chosen, and, using local anaesthesia, it will be resected. The specimens will be sent to the oral and maxillofacial pathology diagnostic service of the University of Basque Country for anatomopathological study
Study: NCT06046170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.
Study: NCT06426355

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NMN
Description: NMN capsules (total of 600mg/day) for 2-5 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NMN-free placebo capsules for 2-5 months
Study: NCT06046170

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive treatment as usual at a community mental health center, including receiving skills training.
Study: NCT06122311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: N-acetylcysteine sachets 600 mg twice daily